CLINICAL TRIALS PROFILE FOR DELSTRIGO
✉ Email this page to a colleague
All Clinical Trials for DELSTRIGO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02629822 ↗ | Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2016-01-14 | The primary objectives of this study are to evaluate the antiretroviral activity and the safety/tolerability of open-label doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF; MK-1439A; DELSTRIGO™) consisting of a single fixed-dose combination (FDC) tablet of DOR/3TC/TDF 100 mg/300 mg/300 mg in treatment-naïve HIV-1 infected participants with select non-nucleoside reverse transcriptase inhibitor (NNRTI) transmitted resistance-associated mutations. |
| NCT04233372 ↗ | Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study | Recruiting | Dr. Josep Mallolas | Phase 4 | 2020-08-27 | Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis. |
| NCT04233372 ↗ | Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study | Recruiting | David Garcia Cinca | Phase 4 | 2020-08-27 | Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis. |
| NCT04283656 ↗ | Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women | Not yet recruiting | Thomas Jefferson University | Phase 1 | 2022-01-03 | Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy typically consists of oral estradiol and spironolactone, which induce drug-metabolizing enzymes after prolonged administration. This study evaluates the bi-directional potential drug interaction between the antiretroviral drug, doravirine, when co-administered with estradiol and spironolactone. |
| NCT04429152 ↗ | ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance | Recruiting | Professor Francois Venter | Phase 3 | 2021-02-09 | This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance |
| NCT04429152 ↗ | ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance | Recruiting | Willem Daniel Francois Venter | Phase 3 | 2021-02-09 | This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DELSTRIGO
Condition Name
Clinical Trial Locations for DELSTRIGO
Trials by Country
Clinical Trial Progress for DELSTRIGO
Clinical Trial Phase
Clinical Trial Sponsors for DELSTRIGO
Sponsor Name
